C&R Research Inc is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center.

Employees

486

Sector

Biotechnology & Medical Research

Calendar

12-29 Ex-dividend date - 50 KRW

More about the company

Quotes

Date	Price	Change	Volume
09/11/26	₩1,997.00	+2.67%	12,204
06/11/26	₩1,945.00	-0.92%	2,693
05/11/26	₩1,963.00	0.00%	3,956
04/11/26	₩1,963.00	-1.11%	16,796
03/11/26	₩1,985.00	-2.46%	3,603

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 09/11/2026			5-day change	1st Jan Change
1,997.00 ^KRW	+2.67%		-1.87%	-55.62%

11-03	C&R Research Inc. announces Annual dividend, payable on April 09, 2027	CI
03-30	C&R Research Inc wins 11.5 billion won order	RE

Market Cap	22.95B 17.06M 15.23M 14.01M 12.72M 24.1M 1.6B 24.7M 168M 66.81M 856M 64.04M 62.67M 2.7B	P/E 2024	17.1x	P/E 2025	20x
Enterprise Value	20.28B 15.07M 13.45M 12.38M 11.24M 21.29M 1.41B 21.82M 148M 59.03M 756M 56.58M 55.37M 2.38B	EV / Sales 2024	0.98x	EV / Sales 2025	0.75x
Free-Float	36.73%	Yield 2024	0.86%	Yield 2025	1.11%

11-03	C&R Research Inc. announces Annual dividend, payable on April 09, 2027	CI
03-30	C&R Research Inc wins 11.5 billion won order	RE
11-05	C&R Research Inc. announces Annual dividend, payable on April 13, 2026	CI
22/03/23	C&R Research Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
07/12/21	C&R Research Co., Ltd. completed the acquisition of NH Special Purpose Acquisition 17 Company in a reverse merger transaction.	CI
22/06/21	C&R Research Co., Ltd. signed an agreement to acquire NH Special Purpose Acquisition 17 Company in a reverse merger transaction.	CI
17/09/20	Nh Special Purpose Acquisition 17 Company has completed an IPO in the amount of KRW 12 billion.	CI
01/07/20	Nh Special Purpose Acquisition 17 Company has filed an IPO.	CI

1 day	+2.67%
1 week	-1.87%
Current month	-5.80%
1 month	-14.11%
3 months	+5.33%
6 months	-43.27%
Current year	-55.62%

C&R Research Inc. Share Price

Stocks

A359090

KR7359090008

Biotechnology & Medical Research

Valuation: C&R Research Inc.

Chart: C&R Research Inc.

Latest news: C&R Research Inc.

Press Releases: C&R Research Inc.

Quotes and Performance

Price Extremes

Managers and Directors: C&R Research Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	1,880	2,005
1 month	1,880	2,390
Current year	1,667	4,870
1 year	1,667	5,890
3 years	1,667	11,975
5 years	1,667	13,400
10 years	1,667	13,400

Manager	Title	Age	Since
Moon-Tae Yoon CEO	Chief Executive Officer	75	07/12/2021
Kyu-Sun Moon DFI	Director of Finance/CFO	49	-
Byeong-in Ahn PSD	President	56	-

Director	Title	Age	Since
Moon-Tae Yoon BRD	Director/Board Member	75	07/12/2021
Jung-Hee Park BRD	Director/Board Member	62	27/10/2021
Byung-In Yoon BRD	Director/Board Member	46	-

Date	Insider	Type	Quantity	% Market Cap.
22/12/24	Yun-ho Kim	Sell	73,163	0.1290%
23/09/24	Jin-hak Kim	Buy	6,675	0.0118%
23/09/24	Jin-hak Kim	Buy	13,325	0.0236%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
C&R RESEARCH INC.	+2.67%	-1.87%	-56.01%	-67.42%	17.06M
WUXI APPTEC CO., LTD.	+2.24%	+8.40%	+58.47%	+69.00%	68.22B
ARGENX SE	+0.63%	+9.00%	+15.38%	+89.26%	59.82B
LONZA GROUP AG	+0.76%	+1.84%	+24.38%	+98.51%	56.07B
BEONE MEDICINES AG	+2.55%	+15.52%	+30.43%	+120.17%	47.67B
IQVIA HOLDINGS INC.	+2.58%	+7.89%	+32.49%	+45.30%	45.95B
REVOLUTION MEDICINES, INC.	+4.09%	+6.37%	+228.06%	+899.75%	43.29B
CELLTRION, INC.	-0.47%	+9.38%	+27.53%	+52.40%	35.66B
GENMAB A/S	-0.03%	-0.86%	+96.59%	+71.25%	34.73B
INSMED INCORPORATED	+1.48%	+6.21%	-38.80%	+395.73%	25.47B
Average	+1.72%	+6.79%	+41.85%	+177.39%	42B
Weighted average by Cap.	+1.66%	+7.83%	+53.82%	+184.10%

	2024	2025
Net sales	59.69B 44.37M 39.6M 36.44M 33.08M 62.68M 4.16B 64.24M 436M 174M 2.23B 167M 163M 7.01B	64.98B 48.31M 43.12M 39.68M 36.01M 68.24M 4.53B 69.94M 475M 189M 2.42B 181M 177M 7.63B
Net income	3.84B 2.85M 2.55M 2.34M 2.13M 4.03M 267M 4.13M 28.04M 11.17M 143M 10.71M 10.48M 451M	2.59B 1.92M 1.72M 1.58M 1.43M 2.72M 180M 2.78M 18.88M 7.53M 96.45M 7.21M 7.06M 304M
Net Debt	-7.67B -5.7M -5.09M -4.69M -4.25M -8.06M -535M -8.26M -56.05M -22.34M -286M -21.41M -20.95M -902M	-2.67B -1.99M -1.77M -1.63M -1.48M -2.81M -186M -2.88M -19.53M -7.78M -99.75M -7.46M -7.3M -314M